18 Jul Ernexa Therapeutics
Sanjeev Luther, President & CEO
Oct. 7 | 2:45pm | FLW Ballroom F
Cambridge, MA
(NASDAQ: ERNA)
Precisely Engineered Cells. Powerful Therapeutics. At Eterna we believe the body holds powerful tools for healing. Our job is to help reactivate them. Through innovative stem cell therapies, we’re breaking through the biological defenses of cancer and autoimmune disease what illness tries to erase: strength, resilience, and hope. Our core technology focuses on engineering induced pluripotent stem cell (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solutions without needing patient-specific cell harvesting. ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-102 is acell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer and ERNA 102 for RA.
